SCM lands Buccolam trial supply contract
SCM Pharma will make trial supplies of Auralis’ trail stage childhood epilepsy drug Buccolam, under a new manufacturing contract announced this week.
Buccolam, which is being developed by Auralis’ in collaboration with Therakind, is an oromucosal solution of midazolam hydrochloride that is designed to provide rapid relief via delivery through the lining of the mouth.
UK contract manufacturing organisation (CMO) SCM has already completed a feasibility study, scale-up batch production and is currently undertaking a two-year stability study.
SCM managing director Shirley Dann said: “We are working closely with the team at Auralis in order to help them be first to market with their innovative product. Our role in the project involves filling, packaging, labelling and delivering the patient-ready dosage forms to the clinical trial sites in Europe.
